Optimization of pathogenetic therapy in patients with chronic obstructive lung disease

The aim of the study is to increase the effectiveness of the treatment of exacerbation of COPD group B GOLD II with the use of combined therapy of the combined drug PulmoBRIZ containing two components - ambroxol and acetylcysteine and the course of halotherapy.

Materials and methods: We observed 60 patients with COPD B, GOLD II. They were divided into two groups: the first - the main (n=30) - patients receiving basic therapy, mucolytic therapy - a combination of Ambroxol and acetylcysteine - 200/30 to 1 tabl. 2 times a day, number 7 days and, from the 3rd day - sessions of halotherapy 1 time per day № 10. The second group, the control group (n=30), followed only basic therapy, did not take mucolytics and halotherapy sessions.

Results: Patients receiving therapy with the combination of ambroxol and acetylcysteine and halotherapy sessions experienced a significant increase in FEV1 by 8.3% (p <0.05); the Tiffon index was 7.2% (p<0.05), reactive anxiety levels (RA) and manifestations of autonomic dysfunction decreased, whereas in patients in the control group these indicators did not improve significantly.

Conclusions: The proposed complex therapy of COPD patients with the inclusion of the combined drug ambroxol and acetylcysteine and halotherapy sessions contributes to the improvement of the quality of life of patients.